News

Hosted on MSN17d
AccuStem to launch MSC blood test for lung cancer screening in US
AccuStem Sciences is set to launch the microRNA Signature Classifier (MSC) blood test for the US lung cancer screening programmes. The company aims to broaden the test's use to the 15 million ...
Pharmabiz5d
INmune Bio to receive US patent for next-generation mesenchymal stromal cell product, CORDStrom
INmune Bio to receive US patent for next-generation mesenchymal stromal cell product, CORDStrom: Boca Raton, Florida Saturday, April 19, 2025, 17:00 Hrs [IST] INmune Bio Inc., a c ...
Business Insider20d
AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States
The test is currently in use as part of the RISP clinical trial and AccuStem is now focused on commercializing the test in the US in 2026. “We see a large opportunity for MSC to meaningfully impact ...
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
Boca Raton, Florida, US, April 16, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune ...